Stéphane Bancel, Moderna CEO (Steven Ferdman/Getty Images)
December 10, 2020 07:01 AM ESTUpdated 09:31 AM
Coronavirus

Covid-19 roundup: Mod­er­na be­gins PhII/III vac­cine study in ado­les­cents; Pfiz­er and BioN­Tech's vac­cine gets an OK in Cana­da as the FDA meets to dis­cuss emer­gency use

Nicole DeFeudis

Editor

Mod­er­na has launched a Phase II/III study of its Covid-19 vac­cine in ado­les­cents younger than 18 and old­er than 12, with the goal of read­ing …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
ENDPOINTS CAREERS

Director of IT, Security

Viridian Therapeutics

Waltham, MA, USA

TRENDING NOW

Lasker Award goes to three sci­en­tists who pi­o­neered re­search be­hind GLP-1 drugs

Ali­gos’ tri­al for oral MASH treat­ment suc­ceeds, but place­bo group shows odd trend

FDA in­spec­tors dis­cov­er trucks car­ry­ing torn-up records leav­ing In­di­an gener­ics fac­to­ry

Ex­clu­sive: Flag­ship-backed Va­lo Health los­es in­ter­im CEO ahead of key Phase 2 read­out

Stem cell start­up spun out of George Church’s lab rais­es $75M

sponsored

Break­ing down si­los with a new quan­ti­ta­tive ap­proach to drug de­vel­op­ment

A service from the Financial Times